Abstract. Thalidomide, a derivative of glutamic acid, has immunosuppressive effects and suppresses graft-vs\x=req-\ host disease in the rat and following bone marrow transplantation in man. It is effectively used in the treatment of erythema nodosum leprosum and has a potential therapeutic effect in a variety of autoimmune diseases. In view of these observations, we evaluated the effect of thalidomide on the incidence of spontaneous and iodine-induced lymphocytic thyroiditis and spontaneous insulin dependent diabetes mellitus in the BB/Wor rat. Thalidomide did not suppress the incidence of lymphocytic thyroiditis and serum anti-thyroglobulin antibodies or affect the serum concentrations of T4, T3 and TSH in this rat model. Thalidomide also did not affect the incidence of insulin dependent diabetes mellitus. In contrast to preliminary studies in man and rat demonstrating efficacy in the therapy of autoimmune diseases, thalidomide did not prevent or suppress autoimmune lymphocytic thyroiditis or insulin-dependent diabetes mellitus in the BB/Wor rat.
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Thalidomide, a derivative of glutamic acid, was originally introduced as a sedative and hypnotic drug (1) . It achieved widespread use because of its apparently low toxicity. Unfortunately, the drug was teratogenic and was withdrawn from general use (2) . However, it was later found to have an immunosuppressive effect. Sheskin first noted that thalidomide was beneficial in the treatment of ery¬ thema nodosum leprosum (3) . After These data suggest that thalidomide is an immu¬ nosuppressive agent. There is no agreement on the mechanism of action of the drug, but it is believed that thalidomide influences T cell regulatory func¬ tions, leading to increased suppressor T cells (6) and decreased helper T cells (7) . Furthermore, it may inhibit neutrophilic chemotaxis (8) , phagocyt¬ osis, and nonspecific inflammatory chemical medi¬ ators (9) .
Lymphocytic thyroiditis is an autoimmune thy¬ roid disease which occurs with an incidence of ap¬ proximately 50% in the insulin-dependent diabetes mellitus prone BB/Wor rat (10) . Excess iodine in¬ gestion markedly increases the incidence of lym¬ phocytic thyroiditis (11) . This (12) (13) (14) (15) . Both cyclosporin-A and silica decrease the incidence of diabetes mellitus in this animal model (16, 17) , and methimazole decreases the incidence of lymphocytic thyroiditis (18 (10) . The cumulative incidence of lymphotic thyroiditis in these rats is approximately 40% by 90 days of age and doubles in the presence of excess iodine ingestion (11) . Thus, in experiment 1, BB/Wor rats received iodine in their drinking water to enhance the incidence of lympho¬ tic thyroiditis. We have very recently observed that 2 sublines of BB/Wor rats, BA and NB lines, have a cumulative incidence of spontaneous lymphocytic thyroiditis of ap¬ proximately 70% by 90 days of age (19) . These 2 sublines were, therefore, used in experiment 2 and iodine was not given since they already have such a high incidence of spontaneous lymphocytic thyroiditis. There are no sexrelated differences in the incidence of either diabetes mellitus or lymphocytic thyroiditis in the BB/Wor rats. (23) , ex¬ perimental allergic neuritis in guinea pigs (23) and rats (24) , and experimental arthus and anaphylactic reactions in guinea pigs (25) . Furthermore, the effect of thalidomide on the survival of skin grafts was inconsistent. Hellman et al. (26) reported that thalidomide prolonged the survival of skin homografts in mice. However, this finding was not con¬ sistently found by other investigators (27) (28) (29) . Nei¬ ther renal transplantation in dogs (30) (33) and inhibit neutrophilic chemotaxis (8) and phagocyt¬ osis (9) . Finally, thalidomide might oppose the effect of chemical mediators at the level of nonspe¬ cific inflammatory responses (9) .
Experimental protocols
In the present study, thalidomide had no effect on the serum (2) (3) (4) (5) mg/kg) and similar to those employed in preventing acute graft-vs-host disease in the rat (5) .
Thus, the failure of thalidomide to decrease the incidence of lymphocytic thyroiditis and diabetes mellitus or to decrease serum anti-Tg antibody levels was probably not due to an insufficient dose of the drug.
The pathogenesis of lymphocytic thyroiditis and insulin-dependent diabetes mellitus in man and ex¬ perimental animal models has not been entirely de¬ fined but is probably due to the combination of cell-mediated and humoral factors in genetically susceptible hosts. Since, as discussed earlier, thali¬ domide appears to have modest suppressive effects on both cell-mediated and antibody associated au¬ toimmune disorders, the failure of the drug to alter the incidence of lymphocytic thyroiditis and diabe¬ tes mellitus in the BB/Wor rat might be due to either its marginal immunosuppressive effect or to its failure to suppress the complex immunologie factors responsible for the occurrence of both dis¬ orders in this rat model.
